Fewer than 5% of people in need are treated with new TB drugs, nearly four years after their approval
3-23 | Companies and countries must take urgent action to increase access to these life-saving treatments Only 4,800 people with drug-resistant tuberculosis (DR-TB) in 2016 were treated with two newer and much more effective medicines, even though these have now been on the market for up to four years, Médecins Sans Frontières (MSF) deplored on 23 March. Outside of a small number of clinical trials and compassionate use programmes, just 469 people received delamanid in 2016, while just over 4,300 received bedaquiline.
12-5 | As negotiators from the 16 countries in the Regional Comprehensive Economic Partnership (RCEP) meet in Tangerang, Indonesia, starting today, Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines. With ratification and implementation of the highly controversial Trans-Pacific Partnership (TPP) trade agreement increasingly in doubt,
11-14 | Pfizer and GlaxoSmithKline (GSK) should extend their price reduction to all developing countries. Médecins Sans Frontières/Doctors Without Borders (MSF) welcomes Pfizer’s decision to lower the price of its pneumococcal conjugate vaccine (PCV) for children caught in humanitarian emergencies.
In lead-up to RCEP trade deal negotiations in China, MSF urges countries not to trade away access to medicines
10-11 | As negotiators for the Regional Comprehensive Economic Partnership (RCEP) trade agreement prepare to meet in Tianjin, China, from 16-22 October, Médecins Sans Frontières (MSF)/Doctors Without Borders urges the 16 negotiating countries to reject any terms in the deal that will harm access to medicines.
9-14 | As UN General Assembly starts, MSF urges governments to set medical research policies that align with people’s health needs New MSF report exposes pharma industry failings and highlights new ways of researching and developing medicines that address public health needs Governments must do more to promote the development of desperately-needed new medicines, vaccines, and diagnostics at affordable prices, urges Médecins Sans Frontières (MSF), in a new report.